Who Generates Higher Gross Profit? Novo Nordisk A/S or Ascendis Pharma A/S

A Tale of Two Danish Giants: Novo Nordisk vs. Ascendis Pharma

In the competitive landscape of the pharmaceutical industry, Novo Nordisk A/S and Ascendis Pharma A/S stand as prominent players from Denmark. Over the past decade, Novo Nordisk has consistently outperformed Ascendis Pharma in terms of gross profit. In 2023, Novo Nordisk's gross profit soared to nearly 197 billion, marking a staggering 1,000% increase compared to Ascendis Pharma's 222 million. This trend has been evident since 2014, with Novo Nordisk maintaining a gross profit at least 1,000 times higher than Ascendis Pharma each year. While Ascendis Pharma has shown growth, particularly with a notable 470% increase in 2023 compared to 2022, it remains dwarfed by Novo Nordisk's financial prowess. This data highlights the significant scale and market dominance of Novo Nordisk in the global pharmaceutical sector.